Biogeography of zooplankton feeding strategy

The trait‐based approach is increasingly used in plankton ecology to understand diversity, community dynamics, and biogeography. While on the global scale phytoplankton traits are fairly well established, zooplankton traits are only beginning to be understood. One taxa‐transcending aspect of zooplankton diversity is the distinction between ambush and active feeding strategies. We present a global‐scale empirical estimate of feeding strategy derived from copepod abundance observations, which for the first time suggests a distinct trait biogeography with ambush feeding as the dominant feeding strategy at higher, but not at lower latitudes. To explain this trait biogeography, we develop a minimalist trade‐off based model of feeding strategies based on encounter rates between zooplankton predators and their phyto‐ and zooplankton prey. Encounter rates are governed by the two traits, size and motility, that trade off against predation risk. Coupled to a three‐dimensional dynamic green ocean model, our idealized encounter model captures the observed feeding strategy biogeography. In the model, this pattern arises from competing dominant food chains within the food web and is shaped by a trophic trait cascade of active vs. passive feeding in adjacent trophic levels. The dominant feeding strategy structures the pathways and efficiency of energy and biomass transfer through the model food web, with consequences for primary production, export and higher trophic levels. Understanding feeding strategies is therefore important for fisheries, biogeochemical cycling, and long‐term predictions of ecosystem dynamics and functioning by global dynamic green ocean models

Pharmacokinetic Modeling of [11C]GSK-189254, PET Tracer Targeting H3 Receptors, in Rat Brain

[Image: see text] The histamine H(3) receptor has been considered as a target for the treatment of various central nervous system diseases. Positron emission tomography (PET) studies with the radiolabeled potent and selective histamine H(3) receptor antagonist [(11)C]GSK-189254 in rodents could be used to examine the mechanisms of action of novel therapeutic drugs or to assess changes of regional H(3) receptor density in animal models of neurodegenerative disease. [(11)C]GSK-189254 was intravenously administered to healthy Wistar rats (n = 10), and a 60 min dynamic PET scan was carried out. Arterial blood samples were obtained during the scan to generate a metabolite-corrected plasma input function. PET data were analyzed using a one-tissue compartment model (1T2k), irreversible (2T3k) or reversible two-tissue compartment models (2T4k), graphical analysis (Logan and Patlak), reference tissue models (SRTM and SRTM2), and standard uptake values (SUVs). The Akaike information criterion and the standard error of the estimated parameters were used to select the most optimal quantification method. This study demonstrated that the 2T4k model with a fixed blood volume fraction and Logan graphical analysis can best describe the kinetics of [(11)C]GSK-189254 in the rat brain. SUV(40–60) and the reference tissue-based measurements DVR(2T4k), BP(ND)(SRTM), and SUV ratio could also be used as a simplified method to estimate H(3) receptor availability in case blood sampling is not feasible

Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D-2 and Histamine H-3 Receptors:A PET Study in Healthy Rats

Introduction: Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor dysfunction and a diverse range of nonmotor symptoms. Functional relationships between the dopaminergic and histaminergic systems suggest that dual-action pharmaceuticals like AG-0029 (D-2/D-3 agonist/H-3 antagonist) could ameliorate both the motor and cognitive symptoms of PD. The current study aimed to demonstrate the interaction of AG-0029 with its intended targets in the mammalian brain using positron emission tomography (PET). Methods: Healthy male Wistar rats were scanned with a small-animal PET camera, using either the dopamine D-2/D-3 receptor ligand [C-11]raclopride or the histamine H-3 receptor ligand [C-11]GSK-189254, before and after treatment with an intravenous, acute, single dose of AG-0029. Dynamic [C-11]raclopride PET data (60 min duration) were analyzed using the simplified reference tissue model 2 (SRTM2) with cerebellum as reference tissue and the nondisplaceable binding potential as the outcome parameter. Data from dynamic [C-11]GSK-189254 scans (60 min duration) with arterial blood sampling were analyzed using Logan graphical analysis with the volume of distribution (V-T) as the outcome parameter. Receptor occupancy was estimated using a Lassen plot. Results: Dopamine D-2/3 receptor occupancies in the striatum were 22.6 +/- 18.0 and 84.0 +/- 3.5% (mean +/- SD) after administration of 0.1 and 1 mg/kg AG-0029, respectively. In several brain regions, the V-T values of [C-11]GSK-189254 were significantly reduced after pretreatment of rats with 1 or 10 mg/kg AG-0029. The H-3 receptor occupancies were 11.9 +/- 8.5 and 40.3 +/- 11.3% for the 1 and 10 mg/kg doses of AG-0029, respectively. Conclusions: Target engagement of AG-0029 as an agonist at dopamine D-2/D-3 receptors and an antagonist at histamine H-3 receptors could be demonstrated in the rat brain with [C-11]raclopride and [C-11]GSK-189254 PET, respectively. The measured occupancy values reflect the previously reported high (subnanomolar) affinity of AG-0029 to D-2/D-3 and moderate (submicromolar) affinity to H-3 receptors

Cosmological Perturbations in Brane-World Theories: Formalism

We develop a gauge-invariant formalism to describe metric perturbations in five-dimensional brane-world theories. In particular, this formalism applies to models originating from heterotic M-theory. We introduce a generalized longitudinal gauge for scalar perturbations. As an application, we discuss some aspects of the evolution of fluctuations on the brane. Moreover, we show how the five-dimensional formalism can be matched to the known four-dimensional one in the limit where an effective four-dimensional description is appropriate.Comment: 16 pages, no figure, matches version to appear in PR

MAMBO Mapping of Spitzer c2d Small Clouds and Cores

AIMS: To study the structure of nearby (< 500 pc) dense starless and star-forming cores with the particular goal to identify and understand evolutionary trends in core properties, and to explore the nature of Very Low Luminosity Objects (< 0.1 L_sun; VeLLOs). METHODS: Using the MAMBO bolometer array, we create maps unusually sensitive to faint (few mJy per beam) extended (approx. 5 arcmin) thermal dust continuum emission at 1.2 mm wavelength. Complementary information on embedded stars is obtained from Spitzer, IRAS, and 2MASS. RESULTS: Our maps are very rich in structure, and we characterize extended emission features (``subcores'') and compact intensity peaks in our data separately to pay attention to this complexity. We derive, e.g., sizes, masses, and aspect ratios for the subcores, as well as column densities and related properties for the peaks. Combination with archival infrared data then enables the derivation of bolometric luminosities and temperatures, as well as envelope masses, for the young embedded stars. CONCLUSIONS: (abridged) Starless and star-forming cores occupy the same parameter space in many core properties; a picture of dense core evolution in which any dense core begins to actively form stars once it exceeds some fixed limit in, e.g., mass, density, or both, is inconsistent with our data. Comparison of various evolutionary indicators for young stellar objects in our sample (e.g., bolometric temperatures) reveals inconsistencies between some of them, possibly suggesting a revision of some of these indicators.Comment: Accepted to A&A. In total 46 pages, with 20 pages of tables, figures, and appendices. High-resolution version of this article at https://www.xythosondemand.com/home/harvard_iic/Users/jkauffma/Public/mambo_spitzer.pd

Early treatment versus expectative management of patent ductus arteriosus in preterm infants

_Background:_ Much controversy exists about the optimal management of a patent ductus arteriosus (PDA) in preterm infants, especially in those born at a gestational age (GA) less than 28weeks. No causal relationship has been proven between a (haemodynamically significant) PDA and neonatal complications related to pulmonary hyperperfusion and/or systemic hypoperfusion. Although studies show conflicting results, a common understanding is that medical or surgical treatment of a PDA does not seem to reduce the risk of major neonatal morbidities and mortality. As the PDA might have closed spontaneously, treated children are potentially exposed to iatrogenic adverse effects. A conservative approach is gaining interest worldwide, although convincing evidence to support its use is lacking. _Methods:_ This multicentre, randomised, non-inferiority trial is conducted in neonatal intensive care units. The study population consists of preterm infants (GA1.5mm. Early treatment (between 24 and 72h postnatal age) with the cyclooxygenase inhibitor(COXi) ibuprofen (IBU) is compared with an expectative management (no intervention intended to close a PDA). The primary outcome is the composite of mortality, and/or necrotising enterocolitis (NEC) Bell stage ≥ IIa, and/or bronchopulmonary dysplasia (BPD) defined as the need for supplemental oxygen, all at a postmenstrual age (PMA) of 36weeks. Secondary outcome parameters are short term sequelae of cardiovascular failure, comorbidity and adverse events assessed during hospitalization and long-term neurodevelopmental outcome assessed at a corrected age of 2 years. Consequences regarding health economics are evaluated by cost effectiveness analysis and budget impact analysis. _Discussion:_ As a conservative approach is gaining interest, we investigate whether in preterm infants, born at a GA less than 28weeks, with a PDA an expectative management is non-inferior to early treatment with IBU regarding to the composite outcome of mortality and/or NEC and/or BPD at a PMA of 36weeks